BMC
AZN icon

Bear Mountain Capital’s AstraZeneca AZN Stock Holding History

Bear Mountain Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$94 – 199
2025
Q4 		$94 Sell
1
-2
-67% -$351 ﹤0.01% 186
2025
Q3 		$416 Buy
+3
New +$454 ﹤0.01% 210

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM

Bear Mountain Capital's AZN Position: Q1 2026 in Review

Bear Mountain Capital sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1 share — an estimated $94 sold.

Bear Mountain Capital first reported a position in AZN in Q3 2025 and held it in 2 quarters. The position peaked at $416 in Q3 2025. 1,386 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Bear Mountain Capital reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Bear Mountain Capital sold 1 AstraZeneca share in Q1 2026, an estimated $94.
  • Bear Mountain Capital first reported a position in AstraZeneca in Q3 2025 and held it in 2 quarters.
  • Bear Mountain Capital's AstraZeneca position peaked at $416 in Q3 2025.
  • 1,386 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Bear Mountain Capital's 13F filing for Q1 2026, filed 12 May 2026.